Trial in Progress: Treatment of Newly-Diagnosed Follicular Lymphoma with Celmod BMS-986369, Rituximab +/- Nivolumab: An Umbrella Phase II Investigator-Initiated Study

Geoff Chong,Jodie B Palmer,Allison A Barraclough,Leonid Churilov,Colm Keane,Sze Ting Lee,Denise Lee,Sumita Ratnasingam,Charmaine Smith,Eliza A Hawkes

Blood（2023）

引用 0|浏览2

暂无评分

摘要

Background: Follicular lymphoma (FL) outcomes are influenced by tumour microenvironment composition and manipulation. As patients (pts) with FL are predominantely aged over 65 and may require treatment multiple times over their disease course, novel regimens which maintain or enhance efficacy and minimise toxicity are highly desirable.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要